Re: cd23mab

[Guest guest]

,

There was a post a week or two ago (I've lost it) that mentioned a cd23 MAB with

the odd name of " Tuscanomab. " I can find no reference to it in PubMed or

anywhere else. If you remember the post can you correct me if I misspelled the

name. I am familiar with the cd23 mab called Lumiliximab now in Phase I/II

trials in Dr Kipps' house but I doubt anyone would mistake Lumilixiimab for

Tuscanomab. Any information would be helpful.

Fred Hummel, 78, Arcata, CA;

CLL/SLL dx 1.98; Fludara 2000;

Rituxan, Fludara, Novantrone,

& Decadron, April-August 2002;

Rituxan X 4, Aug-Sep 2004.

[Guest guest]

Hi Fred,

Tuscanomab is the name given by the professor of Oncology and research at

Medical Center in Sacramento by Doctor Tuscano. He is well known for several

discoveries and unique works involving CLL in the past year or two. He met with

our Sacramento CLL Group formed by of CLL Research about two or three

months ago and he explained one of his discoveries being tested now in the

second phase trials at that is a new monoclonal antibody and when I asked

him what it would be named when it came out for treatment soon he told me that

it would be called Tuscanomab after him. I think he was serious but everyone

was laughing so hard that I didn't get the chance to pin him down. But we will

all be hearing about it before long is my guess. If you want to know more about

Dr. Tuscano or his new monoclonal antibody that will attack the CD-23 marked

Cells you can probably contact at CLL Research and I'm sure he will fill

you in as they have apparently been in close contact.

I hope this is good news, it's nice to see that we have so many new things going

on.

Regards, Kurt

Re: cd23mab

,

There was a post a week or two ago (I've lost it) that mentioned a cd23 MAB

with the odd name of " Tuscanomab. " I can find no reference to it in PubMed or

anywhere else. If you remember the post can you correct me if I misspelled the

name. I am familiar with the cd23 mab called Lumiliximab now in Phase I/II

trials in Dr Kipps' house but I doubt anyone would mistake Lumilixiimab for

Tuscanomab. Any information would be helpful.

Fred Hummel, 78, Arcata, CA;

CLL/SLL dx 1.98; Fludara 2000;

Rituxan, Fludara, Novantrone,

& Decadron, April-August 2002;

Rituxan X 4, Aug-Sep 2004.

[Guest guest]

Kurt,

Thanks for replying to my inquiry about " Tuscanomab " , the new CD23 MAB you wrote

about. I went to the Medical Center website which displayed as UC

Cancer center. I assume that's the facility you were speaking about. I wanted to

find out if the trial you mentioned was still accepting patients.

Unfortunately, searching under leukemia on their clinical trials page, I could

find no trials listed for our disease; all the listings were for myeloid

leukemias. I then looked under the heading 'principal investigators' and didn't

find Dr Tuscano's name listed at all. Perhaps that's not his role at the

hospital but I was disappointed not being able to learn anything at all about

the trial.

I wonder why there's so little public information readily available about this

MAB since it was in it's second phase of testing (Phase II trial?) when the

doctor talked to your group 2 or 3 months ago. Especially when we are

constantly being urged to enroll in clinical trials. Odd, don't you think?

Lumiliximab, the CD23 MAB currently in Phase I/II trials at UCSD, is being given

in combination with FCR. Information about these trials can easily be found on a

number of web locations. I'd sure like to know about the protocol for the

'Tuscanomab' trial. I'm not anxious at all to do FCR but am very interested in

learning if a CD23 MAB given alongside a CD20 MAB might

give better results than the CD20 alone.

Fred Hummel, 78, Arcata, CA;

CLL/SLL dx 1.98; Fludara;

Rituxan, Fludara, Novantrone,

& Decadron; Rituxan; about to

do Rituxan again.